ESM1 May Be Used as a New Indicator for the Diagnosis and Prognosis of Early and Advanced Stage Digestive Tract Cancers
Kui Kang,Ying Wang,Bo Zhang,Zhengxing Xie,Sheng Qing,Yanan Di
DOI: https://doi.org/10.2147/ijgm.s456973
IF: 2.145
2024-06-19
International Journal of General Medicine
Abstract:Kui Kang, 1 Ying Wang, 2 Bo Zhang, 1 Zhengxing Xie, 1 Sheng Qing, 1 Yanan Di 1 1 Department of Gastroenterology, Beijing Aerospace General Hospital, Beijing, People's Republic of China; 2 Department of Endocrinology, Air Force Specialty Medical Center, Beijing, People's Republic of China Correspondence: Yanan Di, Department of Gastroenterology, Beijing Aerospace General Hospital, 7 Wanyuan North Road, Fengtai District, Beijing, 100076, People's Republic of China, Email Background: The biological function and prognostic significance of endothelial cell specific molecule 1 (ESM1) in various cancers have been validated. This study aimed to explore the expression and clinical diagnosis values in patients with stomach adenocarcinoma (STAD) and esophageal carcinoma (ESCA). Methods: Online database Gene Expression Omnibus was used to screen for abnormally expressed genes in STAD and ESCA. Besides, 36 STAD and 36 ESCA patients were enrolled, and their corresponding control groups were also 36 people each. Reverse transcription-quantitative polymerase chain reaction and Western blot were performed to analyze the expression of ESM1. Overall survival (OS) curve and receiver operating characteristics curve (ROC) analysis were used to assess the prognosis, and the sensitivity and specificity of ESM1 for the diagnosis of STAD and ESCA, respectively. Additionally, the effects of ESM1 on cell viability, migration, and invasion were analyzed by cell counting kit-8, transwell migration and invasion assays. Results: The results showed that the poor OS of STAD and ESCA patients was correlated with high ESM1. Besides, ESM1 was increased in ESCA and STAD in in vivo and in vitro studies. ESM1 has a high accuracy [area under the curve (AUC) > 0.79] at stage I and IV of STAD and ESCA. Knockdown of ESM1 suppressed the cell viability, migration, and invasion and increased the apoptosis rate of AGS and TE1 cells. Conclusion: Our study suggested that ESM1 might be used as a new indicator for the diagnosis and prognosis of early and advanced stage digestive tract cancers. Keywords: STAD, ESCA, ESM1, ROC, diagnosis, prognosis Digestive malignancies refer to a group of different types of cancer that occur in the gastrointestinal tract and related organs. 1 According to a previous study, half of the top ten most common cancers and cancer-related causes of death are digestive tract cancers. 2 Stomach adenocarcinoma (STAD) and esophageal carcinoma (ESCA) are two cancers of the digestive tract with a high incidence. STAD, which is the third leading cause of cancer-related death, is a multifactorial disease that is closely related to dietary habit, genetics, and multiple pathogenic infections. 3 ESCA is the eighth most common cancer in the world with a lower 5-year survival, which is around 15–25%. 4 Regrettably, both STAD and ESCA suffer from a low rate of early-stage diagnosis, which poses a great threat to the prognosis and survival rate of patients. In addition, chemoradiotherapy, molecular targeted therapy and immunotherapy also bring great physical and mental pain and economic burden to STAD and ESCA patients with advanced stage. Therefore, the search for potential biomarkers is of great value for the diagnosis and prognosis of early and advanced stage digestive tract cancers. Endothelial cell specific molecule 1 (ESM1), which is located on chromosome 5q11.2, 5 is a gene that encodes soluble secreted proteoglycans, also known as endorphins. 6,7 ESM1 is expressed in a variety of cells, including human vascular endothelial cells, liver cells, and bronchi and pulmonary submucosal gland cells. 5 ESM1 is involved in regulating endothelial cell function, angiogenesis, inflammation, and other physiological and pathological processes. 8,9 In addition, increasing studies have confirmed the role of ESM1 in different cancers, including ovarian cancer, 10 bladder cancer, 11 and head and neck squamous cell carcinoma. 12 Besides, a recent study indicates that ESM1 promotes the occurrence and development of ESCA, and promotes the malignant behavior of esophageal cancer cells. 13 However, the effects of ESM1 on STAD have not been investigated. In this study, we screened the abnormal gene, ESM1, in STAD and ESCA by microarray dataset analysis, and further explored the effects of ESM1 on overall survival (OS), cell viability, migration, and invasion through clinical and in vitro studies, which might provide new ideas for the diagnosis and prognosis of early and advanced stage STAD and ESCA. We searched for STAD and ESCA datasets from the Gene Expression Omnibus (GEO, <u -Abstract Truncated-
medicine, general & internal